Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ruth Namuyinga"'
Autor:
Vaishali Patadia, Katrin Manlik, Geoff Gipson, Jenna C. Willis, Ruth Namuyinga, Rachel McDermott, Anita Shaw, Mary K. Miller, Julius Asubonteng, Negar Golchin, Stephanie von Klot
Purpose TransCelerate BioPharma conducted a survey of biopharmaceutical companies to evaluate current practice and identify opportunities to complement safety signal assessment with rapid real-world data (RWD) analysis. Methods A voluntary 30-questio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b7c3de0d19decc74af67aae8a5e05d7
https://doi.org/10.22541/au.168388398.87324053/v1
https://doi.org/10.22541/au.168388398.87324053/v1
Autor:
Karen E S, Hamre, Baby, Pierre, Ruth, Namuyinga, Kimberly, Mace, Eric W, Rogier, Venkatachalam, Udhayakumar, Jacques, Boncy, Jean Frantz, Lemoine, Michelle A, Chang
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
Chloroquine remains the first-line treatment for uncomplicated malaria in Haiti, and until recently, sulfadoxine–pyrimethamine was the second-line treatment. A few studies have reported the presence of molecular markers for resistance in Plasmodium
Autor:
Ruth Namuyinga, Anskar Y.H. Leung, Markus P. Radsak, Siddhartha Ganguly, Brian A. Jonas, Donna E. Hogge, Pau Montesinos, Alwin Krämer, Nanxiang Ge, Mark J. Levis, Nigel H. Russell, Simona Sica, Melissa Holmes, Hervé Dombret, Giovanni Martinelli, Meena Arunachalam, Samer K. Khaled, Jorge E. Cortes, Yufen Zhang, Priyanka Mehta, Alexander E. Perl, Ken Kobayashi, Antoine Yver
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Background Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5318c9e22ca5af75030b02047cbe80eb
http://hdl.handle.net/10807/170049
http://hdl.handle.net/10807/170049
Autor:
Arnaud Lesegretain, Samer K. Khaled, Derek E. Mires, Nigel H. Russell, Alwin Krämer, Guy Gammon, Yufen Zhang, Alexander E. Perl, Meena Arunachalam, Giovanni Martinelli, Ruth Namuyinga, Mark J. Levis, Siddhartha Ganguly, Jorge E. Cortes
Publikováno v:
Blood. 134:736-736
Introduction: In the phase 3 QuANTUM-R trial, once-daily, oral, highly potent and selective FLT3 inhibitor Q improved clinical benefits vs SC (median overall survival [mOS], 6.2 vs 4.7 mo [HR, 0.76 (95% CI, 0.58-0.98); P = .02]; composite complete re
Autor:
Ruth Namuyinga, Jorge E. Cortes, Jeanne Mendell, Mark J. Levis, Giovanni Martinelli, Youngsook Choi, Alexander E. Perl, Yibin Wang, Nabil Said, Tsvetomir Mitov, Siddhartha Ganguly, Nigel H. Russell, Alwin Krämer, Samer K. Khaled, Hoang Pham, Ben Kim
Publikováno v:
Blood. 134:1372-1372
Background: Quizartinib is a once-daily, oral, highly potent and selective FLT3 inhibitor with proven single-agent activity and a manageable safety profile in FLT3-ITD R/R AML. In the global, phase 3 QuANTUM-R study, quizartinib demonstrated a signif
Autor:
Brian A. Jonas, Jorge E. Cortes, Samer K. Khaled, Giovanni Martinelli, Alexander E. Perl, Siddhartha Ganguly, Nigel H. Russell, Alwin Krämer, Hervé Dombret, Donna Hogge, Anskar Y.-H. Leung, Priyanka Mehta, Pau Montesinos, Markus P. Radsak, Simona Sica, Meena Arunachalam, Melissa Holmes, Ken Kobayashi, Ruth Namuyinga, Nanxiang Ge, Antoine Yver, Yufen Zhang, Mark J. Levis
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:S221-S222
Autor:
Hervé Dombret, Meena Arunachalam, Brian A. Jonas, Donna E. Hogge, Yufen Zhang, Nigel H. Russell, Alwin Krämer, Markus P. Radsak, Melissa Holmes, Priyanka Mehta, Anskar Y.H. Leung, Samer K. Khaled, Mark J. Levis, Jorge E. Cortes, Giovanni Martinelli, Ruth Namuyinga, Siddhartha Ganguly, Pau Montesinos, Alexander E. Perl, Simona Sica
Publikováno v:
Annals of Oncology. 30:vi81
Background FLT3-ITD mutations occur in about 25% of patients (pts) with acute myeloid leukemia (AML) and are associated with poor outcomes. Pts with relapsed/refractory (R/R) FLT3-ITD AML have worse prognosis and high unmet medical need. Quizartinib
Autor:
Hervé Dombret, Donna E. Hogge, Pau Montesinos, Yufen Zhang, Anskar Y.H. Leung, Priyanka Mehta, Brian A. Jonas, Siddhartha Ganguly, Mark J. Levis, Markus P. Radsak, Nanxiang Ge, Simona Sica, Antoine Yver, Samer K. Khaled, Ken Kobayashi, Alexander E. Perl, Giovanni Martinelli, Melissa Holmes, Meena Arunachalam, Ruth Namuyinga, Nigel H. Russell, Alwin Krämer, Jorge E. Cortes
Publikováno v:
Blood. 132:563-563
Introduction: FLT3-ITD mutations are among the most common molecular abnormalities in AML, occurring in ≈ 25% of pts. These driver mutations are associated with high leukemic burden and poor prognosis, eg, high risk of relapse, decreased response t
Autor:
Lauren M. Kucirka, Aruna Subramanian, Ruth Namuyinga, Colleen F. Hanrahan, Dorry L. Segev, Andrew L. Singer
Publikováno v:
Current Opinion in Organ Transplantation. 13:400-404
PURPOSE OF REVIEW Recently, four organ recipients were infected with HIV through transplantation, raising questions about current serologic testing policies. Currently, the decision to use enzyme-linked immunosorbent assay or nucleic acid testing, an
Autor:
Jad Al Danaf, Hanan Aboumatar, Sathyanarayanan Elumalai, Bickey H. Chang, Peter J. Pronovost, Ruth Namuyinga, Jill A. Marsteller, Mohammad Shaear
Publikováno v:
Medical care. 53(9)
Background Patient-centered care is integral to health care quality, yet little is known regarding how to achieve patient-centeredness in the hospital setting. The Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey measu